Stephen A. Jannetta

In his practice, Steve advises medical device, biotechnology, healthcare, technology, manufacturing, and financial services companies in capital raising, licensing, and mergers and acquisitions transactions. He represents major healthcare corporations, nonprofit corporations, as well as technology, biotechnology, manufacturing, and medical technology companies on corporate governance matters and large transactions, and assists smaller, emerging companies in all industries in all aspects of their life cycles.

Steve has been an active member of the board of directors for Life Sciences Pennsylvania, the state’s trade association for the life sciences industry, and he twice chaired the association’s annual life sciences conference. He is the honorary consul of the Kingdom of Belgium for the Philadelphia region. Steve also serves as counsel to The Chamber of Commerce of Greater Philadelphia, the Philadelphia region’s nonprofit charged with promoting growth and opportunity in the Philadelphia region.

Serving on various other boards, Steve has been a member of the board of trustees of his alma mater, The Episcopal Academy, a private, coeducational school; and a member of the campaign cabinet of the United Way of Greater Philadelphia & Southern New Jersey. He also is a member of the advisory board for the Hubert J.P. Schoemaker Classic, an annual event benefiting Melmark Inc., a nonprofit organization that provides educational services to children and adults with intellectual challenges.

In addition, Steve previously served on the attorney advisory committee to the Pennsylvania Securities Commission. He was a board member of the Economy League of Greater Philadelphia, and of the board of trustees of Camp Tecumseh, a boys’ summer sports camp. Additionally, he served on the board of directors of the Haverford Civic Association, his local civic association.

As an adjunct professor at his alma mater, the University of Pennsylvania Law School, Steve taught a seminar on the Legal Aspects of Entrepreneurship for eight semesters.

• A major healthcare company in a buyout of a 50% general partner
• A major healthcare company in its sale of a pharmacy benefits management company to a publicly traded company
• A large nonprofit corporation in numerous credit facilities totaling over $2 billion
• A large nonprofit corporation in a complex corporate restructuring
• A publicly traded medical device company in several matters, including various public offerings of common stock, a $200 million credit facility, and in its $1.5 billion sale
• Various public companies on securities offerings, acquisitions, and corporate governance
• A Canadian publicly traded dermatological company on its Nasdaq listing
• An emerging ophthalmologic company on a convertible debt financing
• A major healthcare company in its minority investment in a Medicaid-focused venture
• A major healthcare company in its acquisition of a Medicaid managed care company
• A medical device company in its $48 million initial public offering
• A publicly traded energy company in various billion dollar credit facilities
• A number of technology, biotechnology, and medtech companies in angel and venture capital financing transactions involving an aggregate of more than $300 million